Comparison of SARS-CoV-2 detection in Saliva by real-time RT-PCR and RT-PCR/MALDI-TOF Methods

Matthew M. Hernandez[1,2,#], Radhika Banu[3], Paras Shrestha[3], Armi Patel[3], Feng Chen[3], Liyong Cao[3], Shelcie Fabre[3], Jessica Tan[1,4], Heidi Lopez[3], Numthip Chiu[3], Biana Shifrin[3], Inessa Zapolskaya[3], Vanessa Flores[3], Pui Yiu Lee[3], Sergio Castañeda[5], Juan David Ramírez[5], Jeffrey Jhang[2], Giuliana Osorio[3], Melissa R. Gitman[2,3], Michael D. Nowak[2,3,], David L. Reich[6], Carlos Cordon-Cardo[2], Emilia Mia Sordillo[2,3], Alberto E. Paniz-Mondolfi[2,3,#]

Corresponding authors: alberto.paniz-mondolfi@mountsinai.org; matthew.hernandez@mssm.edu

Affiliations:

[1] Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

[2] Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

[3] Clinical Microbiology Laboratory, Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

[4] The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

[5] Grupo de Investigaciones Microbiológicas-UR (GIMUR), Departamento de Biología, Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.

[6] Icahn School of Medicine at Mount Sinai Department of Anesthesiology Perioperative and Pain Medicine, New York, NY, 10029, USA

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has accelerated the need for rapid implementation of diagnostic assays for detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in respiratory specimens. While multiple molecular methods utilize nasopharyngeal specimens, supply chain constraints and need for easier and safer specimen collection warrant alternative specimen types, particularly saliva. Although saliva has been found to be a comparable clinical matrix for detection of SARS-CoV-2, evaluations of diagnostic and analytic performance across platforms for this specimen type are limited. Here, we compared two methods for SARS-CoV-2 detection in saliva: the Roche cobas® 6800/8800 SARS-CoV-2 real-time RT-PCR Test and the Agena Biosciences MassARRAY® SARS-CoV-2 Panel/MassARRAY® System. Overall, both systems had high agreement with one another, and both demonstrated high diagnostic sensitivity and specificity when compared to matched patient upper respiratory specimens. We also evaluated the analytical sensitivity of each platform and determined the limit of detection of the Roche assay was four times lower than that of Agena for saliva specimens (390.6 v. 1,562.5 copies/mL). Furthermore, across individual target components of each assay, T2 and N2 targets had the lowest limits of detection for each platform, respectively. Together, we demonstrate that saliva represents an appropriate specimen for SARS-CoV-2 detection in two technologies that have high agreement and differ in analytical sensitivities overall and across individual component targets. The addition of saliva as an acceptable specimen and understanding the sensitivity for testing on these platforms can further inform public health measures for screening and detection to combat the COVID-19 pandemic.

43 **INTRODUCTION**

44 Accurate and rapid testing is vital to informing the response to the coronavirus disease 2019
45 (COVID-19) pandemic. Since its inception, nucleic acid amplification testing (NAAT) for SARS-CoV-2
46 RNA in nasopharyngeal (NP) specimens has been the mainstay in diagnosing COVID-19. Collection of
47 such specimens requires sampling by trained healthcare professionals who need materials such as swabs
48 and viral transport medium (VTM) that may not be available in all settings (1–3). Currently, alternative
49 specimen types including anterior nares (AN) and oropharyngeal (OP) specimens have been evaluated
50 and approved for testing.

51 Saliva has recently garnered attention as a potential specimen given its lower discomfort, minimal
52 invasiveness, and ability to be self-collected. As of February 21, 2021, nineteen *in vitro* SARS-CoV-2
53 diagnostic tests utilizing saliva as a clinical matrix have been approved for Emergency Use Authorization
54 (EUA) by the U.S. Food and Drug Administration (4). Indeed, recent systematic reviews of reported
55 studies demonstrated that saliva NAAT diagnostic performance is comparable to that of NP specimens,
56 particularly in the ambulatory setting (5, 6). While studies have compared detection of SARS-CoV-2
57 across matched NP and saliva specimens, there is large variability in specimen collection, processing
58 methods, and testing platforms utilized (5–14). Moreover, studies that assess analytical performance of
59 detection in saliva across platforms are lacking.

60 Since the identification of SARS-CoV-2, high-throughput sample processing has been logistically
61 difficult to achieve given a number of hurdles including instrument availability and supply chain
62 limitations (15–18). Recently, a novel multiplex reverse transcription (RT-PCR)/MALDI-TOF assay from
63 Agena Bioscience has received EUA (19). The MassARRAY® SARS-CoV-2 Panel and MassARRAY®
64 System has the potential to increase diagnostic capacity and complement current standard NAAT
65 technologies. This is particularly promising for use of saliva for large community-based testing efforts.

66 We therefore evaluated this platform ("Agena") and the more ubiquitous cobas® 6800/8800 SARS-CoV-
67 2 real-time RT-PCR Test ("Roche") to detect SARS-CoV-2 in saliva specimens. Furthermore, we also
68 compared the analytic performance of each platform and each of its component targets.

69 **MATERIALS AND METHODS**

70 We undertook a direct comparison of saliva as a clinical specimen for detection of SARS-CoV-2
71 viral nucleic acids across two platforms in the Clinical Microbiology Laboratory (CML) for the Mount
72 Sinai Health System (MSHS) which is certified under Clinical Laboratory Improvement Amendments of
73 1988 (CLIA), 42 U.S.C. §263a and meets requirements to perform high-complexity tests.

74 **Saliva specimen collection and processing**

75 Saliva specimens were collected from sixty patients who underwent molecular testing for SARS-
76 CoV-2 in NP or AN specimens collected within the previous 48 hours. Saliva specimens were collected
77 in sterile containers (Corning, 352070) and volumes ranged from 0.5 to 1.5 mL. Upon receipt in MSHS
78 CML, 1 mL of viral transport media (VTM) (Hardy Diagnostics, R99) was added to each saliva specimen.
79 These saliva-VTM specimens were vortexed for 30 seconds and 1 mL of each was incubated at 55°C for
80 15 minutes. Processed specimens subsequently underwent side-by-side SARS-CoV-2 nucleic acid
81 detection across two different platforms.

82 **SARS-CoV-2 testing**

83 For testing with the cobas® 6800/8800 SARS-CoV-2 real-time RT-PCR Test (Roche,
84 09175431190), aliquots of processed saliva specimens were run as previously described for NP specimens
85 (20). Briefly, the assay utilizes two targets to detect SARS-CoV-2 RNA: the SARS-CoV-2-specific
86 Orf1ab gene (T1) and the pan-Sarbecovirus envelope E gene (T2). A result was deemed positive for
87 SARS-CoV-2 if both T1 and T2 were detected, or if T1 was detected alone. A result was deemed
88 presumptive positive if T2 was detected alone. A result was deemed negative if neither T1 nor T2 was
89 detected. Target results were valid across all specimens run.

90 For testing with the MassARRAY® SARS-CoV-2 Panel and MassARRAY® System (Agena,
91 CPM384), RNA was extracted from 300 µL of processed specimens using the chemagic™ Viral

92 DNA/RNA 300 Kit H96 (PerkinElmer, CMG-1033-S) on the automated chemagic™ 360 instrument
93 (PerkinElmer, 2024-0020), as per the manufacturer's protocol. To serve as an internal control (IC), MS2
94 phage RNA was included in all extraction steps. Extracted RNA underwent reverse transcription PCR
95 (RT-PCR) with iPLEX® Pro chemistry to amplify the different Agena target regions per the
96 manufacturer's protocol. After the inactivation of unincorporated dNTPs by treatment with shrimp
97 alkaline phosphatase (SAP), a sequence-specific primer extension step was performed, in which a mass-
98 modified terminator nucleotide was added to the probe, using the supplied extension primers and iPLEX®
99 Pro reagents.

100 The extension products (analyte) were desalted, transferred to a SpectroCHIP® Array (a silicon
101 chip with pre-spotted matrix crystal) and then loaded into the MassARRAY® Analyzer (a MALDI-TOF
102 mass spectrometer). For the sample analysis, the analyte/matrix co-crystals were irradiated by a laser,
103 inducing desorption and ionization. The positively charged molecules accelerated into a flight tube
104 towards a detector. Separation occurred by time-of-flight, which is proportional to the mass of the
105 individual molecules. After data processing, a spectral fingerprint was generated for each analyte that
106 characterizes the mass/charge ratio of the molecules (x-axis) as well as their relative intensity (y-axis).
107 Data acquired by the MassARRAY® Analyzer was processed with the MassARRAY® Typer software and
108 then the SARS-CoV-2 Report software. The assay was designed to detect five viral targets: three in the
109 nucleocapsid (N) gene (N1, N2, N3) and two in the Orf1ab gene (ORF1, Orf1ab). If the MS2 IC was
110 detected, results were interpreted as positive if at least two targets were detected or negative if less than
111 two targets were detected. If MS2 IC was not detected and no targets were detected, the result was
112 interpreted as invalid and required rerunning of the specimen.

113 **Limit of detection of SARS-CoV-2 nucleic acid in saliva**

114 The limit of detection (LoD) was determined across both platforms using known concentrations
115 of a SARS-CoV-2 standard spiked into saliva clinical matrix.

116 Briefly, an in-house SARS-CoV-2 standard was generated by pooling 59 NP specimens that
117 previously tested positive at MSHS CML (average T1 cycle threshold (Ct) = 17.53, average T2 Ct =
118 17.59). To quantitate the standard, three dilutions of the pooled sample were made (e.g., 1:50,000 (D1),
119 1:100,000 (D2), 1:200,000 (D3)) and run alongside serial dilutions of a commercially available standard
120 (ZeptoMetrix, NATSARS(COV2)-ERC) on the Roche platform which has EUA from the FDA for SARS-
121 CoV-2 detection in NP specimens. All reactions were run in triplicate and SARS-CoV-2-negative NP
122 matrix served as the diluent. Concentrations of each standard dilution was determined by extrapolation
123 from standard curves generated across T1 and T2 targets (Fig. S1) for each dilution. The stock
124 concentration was, in turn, calculated as the average of the extrapolated stock concentrations determined
125 at each dilution. Aliquots (50 µL) of this stock measurand were stored at -80°C to prevent multiple freeze-
126 thaw cycles.

127 To simulate collection of saliva for testing, saliva from healthy donors was combined in equal
128 parts with VTM and spiked with the SARS-CoV-2 measurand. Serial dilutions of the spiked saliva-VTM
129 specimens were generated in 50-mL conical vials (Corning 352070) over a range of 3,125.0 – 97.7
130 copies/mL (cp/mL) and 12,500 – 195.3 cp/mL for testing on the Roche and Agena platforms, respectively.
131 For each platform, ten replicates of each dilution were generated as well as ten replicates of saliva-VTM
132 spiked with the SARS-CoV-2-negative NP diluent to serve as negative controls. Spiked saliva-VTM
133 specimens were processed and run as described above. SARS-CoV-2 was not detected in any of the
134 negative controls and all results were valid across both platforms.

135 For each platform, the LoD of each overall assay and each target were determined. The
136 experimental LoD represents the lowest concentration with 95% detection. The probit LoD (and 95%
137 fiduciary confidence intervals) was determined by 95% detection based on a probit regression model.

138 **Statistical analyses**

139 For comparison of outcomes across both platforms, percent agreement and Cohen's kappa (κ)
140 statistic were calculated using the attribute agreement analysis on Minitab Statistical Software
141 (19.2020.2.0). Normality was assessed by D'Agostino and Pearson test for continuous variables (e.g., Ct
142 values) (GraphPad Prism 9.0.2). Student's t-test (two-tailed) was performed if data was normally
143 distributed; otherwise, the Mann-Whitney test (two-tailed) was utilized (GraphPad Prism 9.0.2). Simple
144 linear regression analyses were performed across Roche Ct values and serial dilutions. Probit regression
145 modeling assuming Weibull distribution was performed if at least two probit points were available (e.g.,
146 not 100% or 0% detection) (Minitab Statistical Software, 19.2020.2.0). Where depicted, confidence
147 intervals (CI) reflect the 95% level.

148 **RESULTS**

149 Sixty patients who underwent testing for SARS-CoV-2 by NAAT (NP or AN) at MSHS CML
150 were provided with sterile containers for submission of saliva specimens within 48 hours of diagnosis.
151 Saliva specimens were immediately processed and run side-by-side on the Roche and Agena platforms.
152 When compared to paired NP or AN specimens, both platforms had equivalent sensitivities (97.14%, CI:
153 85.08-99.93%) and specificities (100%, CI: 86.28-100%) for saliva specimens.

154 The Roche platform detected SARS-CoV-2 RNA in 34/60 saliva specimens (Table 1). Of the
155 remaining 26, two specimens resulted as presumptive positive and were considered not detected for this
156 study. The Agena platform detected SARS-CoV-2 RNA in 34/60 specimens. Of note, one of the two
157 presumptive positive specimens by Roche was detected by Agena. In addition, the one specimen detected
158 by Roche but not by Agena had the highest T1 Ct (31.62) and second highest T2 Ct (33.68) of all
159 specimens tested. Overall, there was an almost perfect level of agreement across the two platforms
160 (96.67% agreement, CI: 88.47-99.59; Cohen's $\kappa = 0.9321$, $p = 2.6\text{x}10^{-13}$).

161 To preliminarily assess the sensitivity of each platform, we evaluated the performance of
162 component targets across the saliva clinical specimens (Fig. 1). Roche Ct values for each target ranged
163 from 18.80-31.62 for target T1 (Orf1ab gene) and 19.06-37.46 for target T2 (E gene). When compared to
164 the number of targets detected on the Agena platform, all five Agena targets were detected in specimens
165 that had the lowest mean (±SD) Ct values on Roche T1 (24.64±3.019) and T2 (25.26±3.189) targets. The
166 number of Agena targets detected in clinical saliva specimens progressively decreased with increasing Ct
167 values across both Roche targets.

168 We next systematically measured the limit of detection (LoD) of each platform and the component
169 targets. We generated a SARS-CoV-2 standard from high-titer positive NP specimens collected from
170 MSHS patients diagnosed at CML. The titer of the in-house standard was determined by extrapolating

171 concentrations of three dilutions run alongside serial dilutions of a commercial SARS-CoV-2 standard on
172 the Roche platform (Fig. S1). This had the benefit of accounting for any variation in extraction efficiency.

173 The in-house standard was spiked into saliva matrix collected from healthy donors and ten
174 replicates of serial dilutions were run side-by-side on each platform. On the Agena platform, the
175 experimental LoD was determined to be 1,562.5 cp/mL (Table 2) which is slightly lower than the LoD
176 reported by manufacturers for NP clinical matrix (2,500 cp/mL) (19). Across the five different Agena
177 targets, the most sensitive target was the N2 target (1,562.5 cp/mL) followed by the N1 target (3,125
178 cp/mL) (Table 2, Fig. 2A). The least sensitive was the Orf1ab target whose LoD could not be determined
179 from the range of concentrations tested. This reflected a gradient in performance across the individual
180 components on the Agena platform.

181 On the Roche platform, the experimental LoD was lower than that of Agena at 390.6 cp/mL. The
182 Ct values for these saliva specimens demonstrated a linear correlation with the corresponding
183 concentrations across both T1 (R^2=0.9760, p=0.0016) and T2 (R^2=0.9534, p=0.008) (Fig. 2B). Overall,
184 T2 Ct values were higher than T1 Ct values for specimens at the same concentration ($p<0.01$) which is
185 consistent with previous reports for NP specimens (21, 22). While the experimental LoD for T1 and T2
186 targets were determined equivalent, probit analyses suggest the LoD of T2 is, in fact, lower (228.6 cp/mL).
187 However, the fiduciary confidence interval for this value is broad ($151.4\text{-}3.7\times10^{10}$) given that the
188 concentration at which no specimens were detected was not determined in our study.

189 **DISCUSSION**

190 Saliva represents an attractive alternative specimen type for SARS-CoV-2 testing given its limited
191 invasiveness, ability to be self-collected, and reduced need for limited supplies A number of groups have
192 demonstrated that saliva is an acceptable and sensitive specimen type when compared to other upper
193 respiratory (e.g., NP, AN, OP) specimens (5, 8, 9, 12–14). However, analytical performance of this
194 specimen type has yet to be evaluated across the multitude of platforms utilized. In this study, we
195 demonstrate the utility of saliva as a diagnostic specimen across the Roche and Agena platforms. Saliva
196 specimens collected within two days are equivocally sensitive and specific across both methods when
197 compared to matched NP or AN specimens.

198 It is important to note that these two platforms tested are distinguished from each other by their
199 technologic basis and their molecular targets. The Roche platform is like most of the current SARS-CoV-
200 2 molecular diagnostic assays in that it utilizes real-time RT-PCR for detection. However, the Agena
201 platform utilizes mass spectrometry to detect targeted amplicons produced by RT-PCR. While distinct in
202 platform technology, our findings demonstrate comparable diagnostic capabilities of both platforms for
203 detection of SARS-CoV-2 nucleic acids in clinical saliva specimens (Table 1).

204 The platforms we evaluated also differed by SARS-CoV-2 viral targets probed. In contrast to the
205 Roche platform, which is based on two target amplicons (SARS-CoV-2 Orf1ab (T1) and pan-Sarbecovirus
206 E genes (T2)), the Agena platform probes for five targets across two viral genes (3 targets in the
207 nucleocapsid gene (N1, N2, N3), 2 targets in the Orf1ab gene (ORF1, Orf1ab)). This redundancy in viral
208 targets is required to ensure robust sensitivity. When we assessed analytic performance of each target
209 across the clinical saliva specimens, we observed variation in target performance with decreasing viral
210 titers (e.g., Ct values), particularly within the Agena platform (Fig. 1). Specifically, the number of Agena

211 targets detected progressively dropped with decreasing concentration. This suggested inherent analytic
212 differences in the component targets that warrant further investigating.

213 In order to effectively utilize saliva as a clinical specimen for SARS-CoV-2 testing, it is essential
214 to characterize the analytical sensitivity for each diagnostic platform. Most studies have yet to evaluate
215 the LoD across platforms in a standardized method for saliva specimens (reviewed in (6)). Moreover,
216 analytic sensitivity of component targets are often reported as those described by manufacturers or are not
217 systematically evaluated, reported, nor compared across platforms (6, 7, 23–25). Our study demonstrates
218 a greater sensitivity in the Roche platform for saliva specimens overall (Fig. 2). We also demonstrate that
219 across both platforms, there are some targets which are more sensitive than others such as N2 in Agena
220 and T2 in Roche (Fig. 2, Table 2). These metrics are vital as they can inform how diagnostic labs address
221 new circulating viral variants that have mutations that may interfere with multiple detection methods.

222 Our study does have limitations in that our saliva collection methods did not occur at one time
223 point but rather at any point in the day within two days of initial NP/AN collection. While the utility of
224 standardized collection methods (e.g., early morning collection) remain to be further clarified, this is not
225 a variable we controlled in this study. In addition, we utilized a pooled positive NP specimen to serve as
226 our analyte to assess sensitivity. As a result, the sensitivities measured are based on a potentially
227 heterogenous mixture of viral variants. We addressed this by pooling specimens isolated from two
228 consecutive days to ensure a sampling of the predominant circulating clade virus at the given time period.

229 Overall, we demonstrate comparable analytical performance across two unique diagnostic
230 platforms for detection of SARS-CoV-2 nucleic acids in saliva specimens. Given the continued spread
231 and rise of new SARS-CoV-2 variants, there is a critical need to understand the analytic capabilities of
232 these technologies. This is especially relevant in large-scale screening efforts where saliva has the
233 potential to be further exploited for its utility as a clinical specimen. This greater understanding of assay

234 and target sensitivity is essential to informing both effective detection efforts and broader public health

235 measures to ultimately quell the COVID-19 pandemic.

236 **ACKNOWLEDGMENTS**

237 We thank the members of the MSHS CML for providing any assistance when needed throughout this
238 study. We also would like to thank the patients and healthy donors for providing specimens to complete
239 this study.

240

241 **AUTHOR CONTRIBUTIONS**

242 M.M.H., R.B., P.S., S.F., J.T., A.E.PM., H.L.,M.R.G., M.D.N., and E.M.S. provided clinical samples for
243 the study. M.M.H., R.B., P.S., A.P., F.C., L.C., H.L., N.C., G.O., B.S., I.Z., V.F., P.Y., and, A.E.PM.
244 accessioned clinical samples. M.M.H., R.B., P.S., A.P., F.C., L.C., and A.E.PM. performed limit of
245 detection studies. M.M.H., L.S.G., J.D.R., J.J., D.L.R., C.C.C., E.M.S., and A.E.PM. analyzed,
246 interpreted, or discussed data. M.M.H. and A.E.PM. wrote the manuscript. M.M.H., R.B., and A.E.PM.
247 conceived the study. M.M.H., R.B., and A.E.PM. supervised the study. DLR raised financial support.

248

249 **COMPETING INTERESTS**

250 The authors have no conflicts or competing interests to disclose.

251 **REFERENCES**

252 1. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020.
253 Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection
254 of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol 58.

255 2. Kaul KL. 2020. Laboratories and Pandemic Preparedness: A Framework for Collaboration and
256 Oversight. J Mol Diagn 22:841–843.

257 3. Zehnbauer B. 2021. Diagnostics in the Time of Coronavirus Disease 2019 (COVID-19):
258 Challenges and Opportunities. J Mol Diagn 23:1–2.

259 4. Febraury 17, 2021. In Vitro Diagnostics EUAs. US Food and Drug Administration.

260 5. Butler-Laporte G, Lawandi A, Schiller I, Yao MC, Dendukuri N, McDonald EG, Lee TC. 2021.
261 Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection
262 of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Intern Med
263 https://doi.org/10.1001/jamainternmed.2020.8876.

264 6. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021. Performance of Saliva,
265 Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A Systematic
266 Review and Meta-analysis. J Clin Microbiol https://doi.org/10.1128/JCM.02881-20.

267 7. Yee R, Truong TT, Pannaraj PS, Eubanks N, Gai E, Jumarang J, Turner L, Peralta A, Lee Y, Dien
268 Bard J. 2021. Saliva Is a Promising Alternative Specimen for the Detection of SARS-CoV-2 in
269 Children and Adults. J Clin Microbiol 59.

270 8. Procop GW, Shrestha NK, Vogel S, Van Sickle K, Harrington S, Rhoads DD, Rubin BP, Terpeluk
271 P. 2020. A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of
272 SARS-CoV-2 in Symptomatic Patients. J Clin Microbiol 58.

273 9. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren
274 JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A,
275 Lu-Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR,
276 Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T,
277 Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Weizman O-E, Wong P,
278 Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A,
279 Grubaugh ND, Ko AI. 2020. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-
280 CoV-2. N Engl J Med 383:1283–1286.
281 10. Ceron JJ, Lamy E, Martinez-Subiela S, Lopez-Jornet P, Capela E Silva F, Eckersall PD,
282 Tvarijonaviciute A. 2020. Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2: A
283 General Perspective. J Clin Med Res 9.
284 11. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, Pabbi A, Hannam-Clark
285 S, Charles M, Dittrick M, Gadkar VJ, Pernica JM, Hoang LMN. 2021. Self-collected Saline Gargle
286 Samples as an Alternative to Healthcare Worker Collected Nasopharyngeal Swabs for COVID-19
287 Diagnosis in Outpatients. J Clin Microbiol https://doi.org/10.1128/JCM.02427-20.
288 12. Zhu J, Guo J, Xu Y, Chen X. 2020. Viral dynamics of SARS-CoV-2 in saliva from infected
289 patients. J Infect.
290 13. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-
291 C, Chik TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon
292 RW-S, Luo C-T, Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020.
293 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody
294 responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis
295 20:565–574.

296 14. Teo AKJ, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, Cheng LTE, Oon LLE, Tan MH,
297 Chan KS, Hsu LY. 2021. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis
298 of asymptomatic and mild COVID-19 infection. Sci Rep 11:3134.
299 15. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. 2021. Considerations for
300 diagnostic COVID-19 tests. Nat Rev Microbiol 19:171–183.
301 16. Lamprou DA. 2020. Emerging technologies for diagnostics and drug delivery in the fight against
302 COVID-19 and other pandemics. Expert Rev Med Devices 17:1007–1012.
303 17. Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, Yassine HM, Nasrallah
304 GK. 2020. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses
305 12.
306 18. Sheridan C. 2020. Coronavirus and the race to distribute reliable diagnostics. Nat Biotechnol
307 38:382–384.
308 19. Agena Bioscience, Inc. 2021. MassARRAY® SARS-CoV-2 Panel Instructions for Use.
309 20. Hernandez MM, Gonzalez-Reiche AS, Alshammary H, Fabre S, Khan Z, van De Guchte A, Obla
310 A, Ellis E, Sullivan MJ, Tan J, Alburquerque B, Soto J, Wang C-Y, Sridhar SH, Wang Y-C, Smith
311 M, Sebra R, Paniz-Mondolfi AE, Gitman MR, Nowak MD, Cordon-Cardo C, Luksza M, Krammer
312 F, van Bakel H, Simon V, Sordillo EM. 2021. Before the surge: Molecular evidence of SARS-
313 CoV-2 in New York city prior to the first report. bioRxiv. medRxiv.
314 21. Mostafa HH, Hardick J, Morehead E, Miller J-A, Gaydos CA, Manabe YC. 2020. Comparison of
315 the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular
316 assays. J Clin Virol 130:104578.

317 22. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H,
318 Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection Assays
319 Using Seven Different Primer-Probe Sets and One Assay Kit. J Clin Microbiol 58.
320 23. SoRelle JA, Mahimainathan L, McCormick-Baw C, Cavuoti D, Lee F, Bararia A, Thomas A,
321 Sarode R, Clark AE, Muthukumar A. 2020. Evaluation of symptomatic patient saliva as a sample
322 type for the Abbott ID NOW COVID-19 assay. bioRxiv. medRxiv.
323 24. Lu J, Becker D, Sandoval E, Amin A, De Hoff P, Diets A, Leonetti N, Lim YW, Elliott C, Laurent
324 L, Grzymski J. 2020. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in
325 the community setting. bioRxiv. medRxiv.
326 25. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W,
327 Sungkanuparph S, Phuphuakrat A. 2021. Saliva sample as a non-invasive specimen for the
328 diagnosis of coronavirus disease 2019: a cross-sectional study. Clin Microbiol Infect 27:285.e1-
329 285.e4.

330 **TABLES**

331

332 **Table 1.** Detection of SARS-CoV-2 nucleic acids in saliva across Roche and Agena commercial

333 systems

334
335

		Roche		
		Positive	Negative	**Total**
Agena	Positive	33	1*	34
	Negative	1	25	26
	Total	34	26	60

*Presumptive positive by Roche

336

337 **Table 2.** LoD of SARS-CoV-2 nucleic acids in spiked saliva on the Agena MassARRAY® platform
338

	No. detected / No. tested at viral concentrations (cp/mL):									Probit	
	12500	**6250**	**3125**	**1562.5**	**781.3**	**390.6**	**195.3**	**0.0**	**Exp LoD[a]**	**LoD[b]**	**95% CI[c]**
Overall	10/10	10/10	10/10	10/10	1/10	0/10	0/10	0/10	1562.5	NA	NA
N1	10/10	10/10	10/10	9/10	2/10	0/10	0/10	0/10	3125.0	1745.5	(1336, 4069)
N2	10/10	10/10	10/10	10/10	1/10	0/10	0/10	0/10	1562.5	NA	NA
N3	10/10	10/10	4/10	1/10	0/10	0/10	0/10	0/10	6250.0	5257.8	(3989, 12801)
ORF1	10/10	10/10	8/10	8/10	0/10	0/10	0/10	0/10	6250.0	3544.7	(2502, 8161)
Orf1ab	0/10	0/10	0/10	0/10	0/10	0/10	0/10	0/10	>12500	NA	NA

339 [a]Experimental (Exp) LoD determined by concentration at which detection is ≥95%
340 [b]LoD determined by probit analysis. "NA" reflects inability to perform probit analyses due to lack of sufficient probit points
341 [c]95% fiduciary confidence interval

342 **FIGURES**

343

344 **Fig. 1. Quantitative comparison of SARS-CoV-2 targets detected in clinical saliva specimens.**

345 Scatter plots depict the number of SARS-CoV-2 targets on the Agena platform detected and the

346 corresponding Roche cycle threshold (Ct) for each clinical saliva specimen. (A) Ct values for Roche

347 target T1 (Orf1ab) and (B) Roche target T2 (E gene) are depicted for individual clinical saliva

348 specimens. Medians are depicted in each column. Statistically significant differences are depicted (e.g.,

349 *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$, ****, $p<0.0001$) based on student's t-test or Mann-Whitney non-

350 parametric test depending on whether data was normally distributed (see Methods).

Fig. 1


A
Roche T1 Ct
15
20
25
30
35
40
0
1
2
3
4
5
Agena Targets Detected
*
***
**
B
Roche T2 Ct
15
20
25
30
35
40
0
1
2
3
4
5
Agena Targets Detected
*
****
**

351 **Fig. 2. Evaluation of Roche and Agena SARS-CoV-2 target sensitivity.** (A) Bar graph depicts
352 percent of spiked saliva specimens detected overall by the Agena MassARRAY® platform at five
353 different concentration (log). Overlaid are the individual sensitivities of the five Agena targets at each
354 concentration. (B) Scatter plot of Ct values of Roche T1 (pink) and T2 (blue) targets across
355 concentrations (log) of spiked saliva specimens at six different concentrations. Mean, standard error of
356 the mean, and line of best fit with 95% confidence intervals are depicted for each target. Above each
357 concentration is the percent of replicates detected by T1 or T2 targets.

Fig. 2


A
Agena Percent Detected
100%
80%
60%
40%
20%
0%
2.0
2.5
3.0
3.5
Log(cp/mL)
Overall
N1
N2
N3
ORF1
Orf1ab
B
0% 30% 100% 100% 100% 100%
60% 90% 100% 100% 100% 100%
Roche Ct Value
30
32
34
36
2.0
2.5
3.0
3.5
Log(cp/mL)
T1
T2

358 **SUPPLEMENTAL FIGURES**

359

360 **Fig. S1. Quantitation of in-house SARS-CoV-2 standard.** Linear regression of commercial standard
361 in negative NP matrix run alongside three dilutions of pooled positive SARS-CoV-2 NP clinical
362 specimens. (A) Mean (±SEM) Roche target T1 Ct values and (B) target T2 Ct values of seven serial
363 dilutions of commercial standard plotted with lines of best fit. Correlation coefficients and p-values are
364 annotated for each standard curve. Concentrations for three dilutions (D1, D2, D3) of in-house standard
365 were extrapolated from T1 and T2 lines of best fit (dotted green lines) to determine the concentration of
366 the in-house standard.

367

Fig. S1


A
Roche T1
R2 = 0.9653
p<0.0001
Ct
36
34
32
30
28
D3
D2
D1
2.0
2.5
3.0
3.5
4.0
Log(cp/mL)
B
Roche T2
R2 = 0.9639
p<0.0001
Ct
36
34
32
30
28
D3
D2
D1
2.0
2.5
3.0
3.5
4.0
Log(cp/mL)